AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TELIX PHARMACEUTICALS LTD

15.360

-0.290-1.85%

Volume:1.09M

Turnover:16.81M

Market Cap:5.20B

PE:115.40

High:15.590

Open:15.390

Low:15.260

Close:15.650

52wk High:18.320

52wk Low:8.260

Shares:338.72M

Float Shares:275.41M

Volume Ratio:0.85

T/O Rate:0.40%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.133

EPS(LYR):-0.029

ROE:7.36%

ROA:2.71%

PB:7.65

PE(LYR):-521.67

Loading ...

Overview Company News Filings

Stock Track | Telix Pharmaceuticals Soars 7.58% Intraday on Major Regeneron Collaboration Deal

Telix and Regeneron Announce Strategic Radiopharma Collaboration

Telix Pharmaceuticals Ltd - to Receive $40 Mln Upfront and up to $2.1 Bln in Milestones Plus Royalties

THOMSON REUTERS

Telix Pharmaceuticals Ltd-Telix and Regeneron Announce Radiopharma Collaboration

THOMSON REUTERS

Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Amid Lingering Geopolitical Uncertainty, CPI Focus

MT Newswires Live

BUZZ-Australia's Telix Pharmaceuticals rises as US FDA approves drug application

Stock Track | Telix Pharmaceuticals Soars 8.14% Intraday on FDA Acceptance of Brain Cancer Imaging Agent NDA

Telix Pharmaceuticals Says US FDA Accepts New Drug Application for Brain Cancer Imaging Agent

MT Newswires Live

FDA Accepts Nda for Tlx101-Px (Pixclara®)

THOMSON REUTERS

FDA Accepts NDA for TLX101-Px (Pixclara®)

Telix says FDA accepts resubmitted Pixclara glioma PET imaging NDA

Telix Pharmaceuticals Ltd-FDA Accepts Nda for Tlx101-Px (Pixclara)

THOMSON REUTERS

Telix Pharmaceuticals Ltd - FY2026 Guidance Excludes Tlx101-Px Revenue Contribution

THOMSON REUTERS

Telix Pharmaceuticals Ltd-Telix Strengthens Board With Further Director Appointments

THOMSON REUTERS

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Ahead of Trump's Hormuz Reopening Deadline

MT Newswires Live

BUZZ-Australia's Telix Pharmaceuticals jumps on strong Q1 sales

Stock Track | Telix Pharmaceuticals Soars 5.02% Intraday on Strong Q1 Revenue and Reaffirmed Guidance

Telix reaffirms FY 2026 revenue guidance of US$950 million-US$970 million

Telix Pharmaceuticals Ltd - Q1 2026 Unaudited Group Revenue of US$230 Mln

THOMSON REUTERS

Will Telix (ASX:TLX) Board Refresh Subtly Recast Its Governance And Growth Balancing Act?

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/TLX.AU/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TLX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","market":"AU","secType":"STK","nameCN":"TELIX PHARMACEUTICALS LTD","latestPrice":15.36,"timestamp":1788156720000,"preClose":15.65,"halted":0,"volume":1092733,"delay":0,"changeRate":-0.018530351437699738,"nameEN":"TELIX PHARMACEUTICALS LTD","floatShares":275410996,"shares":338721355,"eps":0.13310708320134634,"marketStatus":"Not Yet Opened","change":-0.29,"latestTime":"08-31 16:12:00 AEST","open":15.39,"high":15.59,"low":15.26,"amount":16808567,"amplitude":0.021086,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.13310708320134634,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1788220800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":15.65,"openAndCloseTimeList":[[1788134400000,1788156000000]],"volumeRatio":0.8479013232341317,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"TLX.AU","preClose":15.36,"auctionPrice":15.36,"auctionVolume":529,"auctionTime":1788212867757,"referenceTime":1788172203092,"auction":1,"marketStatus":"盘前竞价","timestamp":1788212867757}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","floatShares":275410996,"roa":"2.71%","roe":"7.36%","lyrEps":-0.029444,"volumeRatio":0.8479013232341317,"shares":338721355,"dividePrice":0,"high":15.59,"amplitude":0.021086,"preClose":15.65,"low":15.26,"week52Low":8.26,"pbRate":"7.65","psRate":"4.19","week52High":18.32,"institutionHeld":0,"latestPrice":15.36,"eps":0.13310708320134634,"divideRate":0,"volume":1092733,"delay":0,"ttmEps":0.13310708320134634,"open":15.39,"prevYearClose":11.2,"prevWeekClose":15.65,"prevMonthClose":15.36,"prevQuarterClose":16.58,"fiveDayClose":16.16,"twentyDayClose":14.28,"sixtyDayClose":13.31},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-20","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787184000000,"name":null,"time":"","dateTimestamp":1787148000000,"actualEps":null},{"date":"2026-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1771455600000,"name":null,"time":"","dateTimestamp":1771419600000,"actualEps":null},{"date":"2026-01-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1768777200000,"name":null,"time":"","dateTimestamp":1768741200000,"actualEps":null},{"date":"2025-08-21","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755734400000,"name":null,"time":"","dateTimestamp":1755698400000,"actualEps":null},{"date":"2025-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739919600000,"name":null,"time":"","dateTimestamp":1739883600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX.AU\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1158547007","title":"Stock Track | Telix Pharmaceuticals Soars 7.58% Intraday on Major Regeneron Collaboration Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=1158547007","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158547007?lang=en_us&edition=fundamental","pubTime":"2026-04-13 08:04","pubTimestamp":1776038653,"startTime":"0","endTime":"0","summary":"TELIX PHARMACEUTICALS LTD (TLX.AU) saw its stock price soar 7.58% during intraday trading on Monday, following a significant corporate announcement.The sharp increase is attributed to the company's...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627101920","title":"Telix and Regeneron Announce Strategic Radiopharma Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2627101920","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627101920?lang=en_us&edition=fundamental","pubTime":"2026-04-13 06:57","pubTimestamp":1776034620,"startTime":"0","endTime":"0","summary":"Telix to receive US$40 million upfront for four initial programs with optionality on a per program basis to co-fund commercialization and profit-share or earnup to an aggregate of US$2.1 billion in developmentand commercial milestone payments pluslow double-digit royalties.","market":"other","thumbnail":"https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/telix-and-regeneron-announce-strategic-radiopharma-collaboration-302739967.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2106854487.HKD","BK4543","LU0889565916.HKD","LU2237438978.USD","SEC.AU","LU0320765992.SGD","LU2023250504.SGD","LU1917777945.USD","LU0882574055.USD","LU0823416689.USD","BK4141","BK4585","BK4526","LU0114720955.EUR","BK4139","BK7067","TLX.AU","REGN","LU2089984988.USD","ASX.AU","LU0289739699.SGD","LU2362540622.SGD","LU0053666078.USD","TLX","LU0058720904.USD","LU2362541273.HKD","LU2468319806.SGD","BK4588","ASX","LU0109394709.USD","BK7039","LU2362541513.USD","LU0823434740.USD","LU1974910355.USD","LU0823434583.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627888101","title":"Telix Pharmaceuticals Ltd - to Receive $40 Mln Upfront and up to $2.1 Bln in Milestones Plus Royalties","url":"https://stock-news.laohu8.com/highlight/detail?id=2627888101","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627888101?lang=en_us&edition=fundamental","pubTime":"2026-04-13 06:28","pubTimestamp":1776032882,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260412:nTUE9FVW25:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2089984988.USD","LU0823434583.USD","LU0058720904.USD","LU0823416689.USD","TLX.AU","BK4588","LU1974910355.USD","LU0109394709.USD","LU0882574055.USD","LU2362541273.HKD","LU0053666078.USD","LU2106854487.HKD","LU2362541513.USD","REGN","BK7067","BK4585","LU0823434740.USD","LU2468319806.SGD","LU0289739699.SGD","LU2023250504.SGD","BK4139","LU2362540622.SGD","LU0889565916.HKD","LU2237438978.USD","LU1917777945.USD","LU0114720955.EUR","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627710900","title":"Telix Pharmaceuticals Ltd-Telix and Regeneron Announce Radiopharma Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2627710900","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627710900?lang=en_us&edition=fundamental","pubTime":"2026-04-13 06:28","pubTimestamp":1776032882,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260412:nTUE9FVW25:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626118762","title":"Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Amid Lingering Geopolitical Uncertainty, CPI Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2626118762","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626118762?lang=en_us&edition=fundamental","pubTime":"2026-04-10 21:15","pubTimestamp":1775826917,"startTime":"0","endTime":"0","summary":"The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.1% and the actively traded Invesco QQQ Trust (QQQ) was 0.1% higher in Friday's premarket activity amid lingering geopolitica","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX.AU","AOS","IYE","IYW","E","SLM.AU","SLM","FDN","XLP","XLY","IYK","SLV","NMG","XLI","BETH","EXI","RTH","XRT","SOXX","XLE","NMG.AU","EQR","IYH","IYJ","VHT.AU","VDC","XLK","FAS","BITO","EEM","USO","IBB","VIS","SPY.AU","SHAK","QQQ","SPY","IGM","VHT","IVV","UNG","GLD","RTH.AU","XLV","FAZ","XLF","TSM","EETH","TLX","XSD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626151448","title":"BUZZ-Australia's Telix Pharmaceuticals rises as US FDA approves drug application","url":"https://stock-news.laohu8.com/highlight/detail?id=2626151448","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626151448?lang=en_us&edition=fundamental","pubTime":"2026-04-10 08:43","pubTimestamp":1775781831,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Telix Pharmaceuticals rises as US FDA approves drug application** Telix Pharmaceuticals TLX.AX rises as much as 8.4% to A$14.79, highest since December 8** Co says U.S. FDA accepts resubmitted New Drug Application for TLX101-Px** TLX101-Px is an investigational Positron emission tomography agent for imaging of glioma ** YTD, TLX up 26.3%  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nL4N40T011:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194270889","title":"Stock Track | Telix Pharmaceuticals Soars 8.14% Intraday on FDA Acceptance of Brain Cancer Imaging Agent NDA","url":"https://stock-news.laohu8.com/highlight/detail?id=1194270889","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194270889?lang=en_us&edition=fundamental","pubTime":"2026-04-10 08:02","pubTimestamp":1775779363,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) saw its shares surge 8.14% during intraday trading on Friday, following a significant regulatory development for one of its key investigational...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626126156","title":"Telix Pharmaceuticals Says US FDA Accepts New Drug Application for Brain Cancer Imaging Agent","url":"https://stock-news.laohu8.com/highlight/detail?id=2626126156","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626126156?lang=en_us&edition=fundamental","pubTime":"2026-04-10 07:25","pubTimestamp":1775777139,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  said the US Food and Drug Administration  has accepted its resubmitted new drug application for TLX101-Px, an investigational positron emission tomography  agent for the imaging of glioma, a form of brain cancer, according to a Friday filing with the Australian bourse.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7047","TLX.AU","PET.AU","BK4139","BK4585","TLX","BK7067","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626815689","title":"FDA Accepts Nda for Tlx101-Px (Pixclara®)","url":"https://stock-news.laohu8.com/highlight/detail?id=2626815689","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626815689?lang=en_us&edition=fundamental","pubTime":"2026-04-10 06:51","pubTimestamp":1775775089,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nTUARRPF8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626156814","title":"FDA Accepts NDA for TLX101-Px (Pixclara®)","url":"https://stock-news.laohu8.com/highlight/detail?id=2626156814","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626156814?lang=en_us&edition=fundamental","pubTime":"2026-04-10 06:50","pubTimestamp":1775775000,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, April 10, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited  today announces that the United States  Food and Drug Administration  has accepted the Company's resubmitted New Drug Application  for TLX101-Px[1], , an investigational PET[3] agent for the imaging of glioma , and has assigned a PDUFA[4] goal date of September 11, 2026.The approval of TLX101-Px will fulfil a significant unmet medical need for the characterization of recurrent or progressive glioma from treatment related changes in both adult and pediatric patients[5]. Neuroimaging of glioma with 18F-FET is already broadly recommended in international clinical practice guidelines – including NCCN Guidelines[6] – and TLX101-Px has been granted Orphan Drug[7] and Fast Track[8] designations by the FDA.Patrick Wen, MD, E. Antonio Chiocca,MD, PhD, Family Endowed Chair in Neuro-Oncology at Mass General Brigham Cancer Institute, added, \"Distinguishing tumor progression from treatment-related c","market":"other","thumbnail":"https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/fda-accepts-nda-for-tlx101-px-pixclara-302738824.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4141","BK7039","LABU","BK7067","BK4526","TLX.AU","BK4135","ASX","CNS","BK4543","SEC.AU","GBM.AU","BK7104","ASX.AU","TLX","BK4588","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626215526","title":"Telix says FDA accepts resubmitted Pixclara glioma PET imaging NDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2626215526","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626215526?lang=en_us&edition=fundamental","pubTime":"2026-04-10 06:37","pubTimestamp":1775774227,"startTime":"0","endTime":"0","summary":"FDA accepted Telix resubmitted NDA for TLX101-Px , an investigational PET imaging agent for glioma.Telix noted no Pixclara revenue included in FY 2026 guidance.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief on April 10, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDLbwm1Py:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626155157","title":"Telix Pharmaceuticals Ltd-FDA Accepts Nda for Tlx101-Px (Pixclara)","url":"https://stock-news.laohu8.com/highlight/detail?id=2626155157","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626155157?lang=en_us&edition=fundamental","pubTime":"2026-04-10 06:26","pubTimestamp":1775773584,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nTUEPBZWJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626150155","title":"Telix Pharmaceuticals Ltd - FY2026 Guidance Excludes Tlx101-Px Revenue Contribution","url":"https://stock-news.laohu8.com/highlight/detail?id=2626150155","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626150155?lang=en_us&edition=fundamental","pubTime":"2026-04-10 06:26","pubTimestamp":1775773584,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nTUEPBZWJ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626786329","title":"Telix Pharmaceuticals Ltd-Telix Strengthens Board With Further Director Appointments","url":"https://stock-news.laohu8.com/highlight/detail?id=2626786329","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626786329?lang=en_us&edition=fundamental","pubTime":"2026-04-09 06:23","pubTimestamp":1775687029,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nTUE28RXQB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625953447","title":"Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Ahead of Trump's Hormuz Reopening Deadline","url":"https://stock-news.laohu8.com/highlight/detail?id=2625953447","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625953447?lang=en_us&edition=fundamental","pubTime":"2026-04-07 21:01","pubTimestamp":1775566895,"startTime":"0","endTime":"0","summary":"The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.6% and the actively traded Invesco QQQ Trust (QQQ) was 0.7% lower in Tuesday's premarket activity, ahead of US President D","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX",".DJI","FAZ","SPY","FAS","IBB","XSD","NMR","MNR","TLX.AU","VIS","XLY","XLK","BETH","XLF","EETH","IYW","QQQ","TSLA","XRT","VHT.AU","SPY.AU","IGM","XLV","EQR","FDN","IYH","UNG","XLP","RDW","INFY","VDC","IYK","PMR","IVV","XLI","VHT","SLV","XLE","RTH.AU","EXI","RTH","USO","IPK","IYJ","GLD","EEM","IYE","BITO","SOXX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625884099","title":"BUZZ-Australia's Telix Pharmaceuticals jumps on strong Q1 sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2625884099","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625884099?lang=en_us&edition=fundamental","pubTime":"2026-04-07 08:41","pubTimestamp":1775522466,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Telix Pharmaceuticals jumps on strong Q1 sales** Telix Pharmaceuticals TLX.AX rises as much as 8% to A$13.99; marks biggest intraday pct gain since March 18** Co posts Q1 2026 Group revenue of $230 million, 11% q/q jump** Reaffirms FY 2026 revenue guidance of $950 million-$970 million** YTD, TLX up 23.5%  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nL4N40Q018:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132660061","title":"Stock Track | Telix Pharmaceuticals Soars 5.02% Intraday on Strong Q1 Revenue and Reaffirmed Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1132660061","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132660061?lang=en_us&edition=fundamental","pubTime":"2026-04-07 08:03","pubTimestamp":1775520235,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd (TLX.AU) saw its stock price soar 5.02% during Tuesday's intraday trading session.The significant upward movement follows the company's release of its unaudited Q1 2026...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625360094","title":"Telix reaffirms FY 2026 revenue guidance of US$950 million-US$970 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2625360094","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625360094?lang=en_us&edition=fundamental","pubTime":"2026-04-07 07:40","pubTimestamp":1775518800,"startTime":"0","endTime":"0","summary":"Outlook follows Q1 2026 unaudited group revenue of US$230 million, up 11% from Q4 2025.Precision Medicine Q1 revenue reached US$186 million, up 16% quarter-over-quarter, supported by growth in Illuccix and Gozellix.R&D spending guidance was reiterated at US$200 million to US$240 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nNDL9WvYlm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","IE00BKPKM429.USD","SG9999014021.USD","IE00BGHQF748.EUR","LU2095319765.USD","BK4585","NDAQ","SG9999014013.SGD","BK7067","SG9999014005.SGD","IE00B3QW5Z07.USD","BK4112","LU2210149790.SGD","TLX.AU","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","BK4588","LU2210150020.SGD","LU0314104364.USD","SG9999014039.USD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625075516","title":"Telix Pharmaceuticals Ltd -  Q1 2026 Unaudited Group Revenue of US$230 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2625075516","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625075516?lang=en_us&edition=fundamental","pubTime":"2026-04-07 06:29","pubTimestamp":1775514540,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nFWN40P0K9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625233628","title":"Will Telix (ASX:TLX) Board Refresh Subtly Recast Its Governance And Growth Balancing Act?","url":"https://stock-news.laohu8.com/highlight/detail?id=2625233628","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625233628?lang=en_us&edition=fundamental","pubTime":"2026-04-06 04:12","pubTimestamp":1775419922,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals recently announced that David Gill will join its Board as a Non-Executive Director on 11 May 2026, with plans for him to succeed Dr. Mark Nelson as Chair while Nelson remains a Non-Executive Director.\nThe appointment brings a veteran life sciences executive with extensive radiopharmaceutical, capital markets and governance experience onto Telix’s Board, potentially reshaping how the company balances growth ambitions with oversight as a dual-listed business.\nWe’ll now...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/will-telix-asxtlx-board-refresh-subtly-recast-its-governance","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/will-telix-asxtlx-board-refresh-subtly-recast-its-governance","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","BK4139","TLX.AU","TLX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":198,"code":"91000000","status":"200"}]}}